Sun Pharmaceutical Industries

Rediff.com » News » Sun Pharmaceutical Industries

News for Sun Pharmaceutical Industries

Business

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate Covid-19 disease. Joining the long list of firms to launch its own......

'Famotidine may become the next HCQ for Covid-19'

Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its......

Market turmoil is bad news for IPOs

Experts said the 20 per cent drop in the market poses a challenge for companies that have set the ball rolling on their IPO plans as valuations will now have to realign. Illustration: Uttam......

Sun Pharma's Dilip Shanghvi takes 99% pay cut

As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore. The founder and managing director (MD) of the country’s largest pharmaceutical firm Sun......

India likely to be among top 20 global FDI sources by 2021

While the UN report said that FDI inflows rose 6 per cent in 2018 to $ 42 billion, the government’s own data for the entire FY19 period has shown that inbound equity investments declined for......

Web results for Sun Pharmaceutical Industries

Sun Pharma's R&D investment around Rs 2,000 cr in FY20

Sun, Sep 27 2020 12:16:12 PM New Delhi, Sep 27 (IANS): Sun Pharmaceutical Industries Ltd invested around Rs 2,000 crore in research and development... ...

https://www.daijiworld.com/news/newsDisplay.aspx?newsID=755381

Sun Pharma bullish on specialty biz, looks to expand the segment to new geographies

Sharing information with shareholders, Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company's strategy of developing the... ...

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-bullish-on-specialty-biz-looks-to-expand-the-segment-to-new-geographies/articleshow/78344062.cms

RIL, Sun Pharma, RITES, IRB Infra, Voda Idea, TCS and Zee Entertainment

Bharti Airtel and Vodafone Idea (Vi), lost 1.12 million and 4.82 million customers respectively in June, in the aftermath of the December 2019... ...

https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-the-news-ril-bharti-airtel-voda-idea-tcs-zee-entertainment/articleshow/78307222.cms

Sun Pharma gains 2% on launching psoriasis drug in Japan

Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its speciality product Ilumya, indicated for the treatment of plaque psor ...

https://www.thehindubusinessline.com/markets/stock-markets/sun-pharma-gains-2-on-launching-psoriasis-treatment-drug-in-japan/article32674603.ece

Sun Pharma Advanced Research gains over 3% on pact with Tripoint Therapeutics

Sun Pharma Advanced Research Company on Tuesday announced the grant of an exclusive licence to Tripoint Therapeutics LLC, USA to commercialise the Ele ...

https://www.thehindubusinessline.com/markets/stock-markets/sun-pharma-advanced-research-gains-over-3-on-pact-with-tripoint-therapeutics/article32666275.ece

See All

Rediff News

Sun Pharmaceutical Industries

News for Sun Pharmaceutical Industries

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

'Famotidine may become the next HCQ for Covid-19'

Market turmoil is bad news for IPOs

Sun Pharma's Dilip Shanghvi takes 99% pay cut

India likely to be among top 20 global FDI sources by 2021

Related Tags

Related Pages

Top Coverage News

US Presidential Elections 2016

Coming to India and making

India, through the eye of a camera

Commonwealth Games - 2014

The defence coverage of Rediff.com